Shares of ResMed Inc. RMD slumped 0.35% to $228.69 Tuesday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index SPX falling 0.43% to 5,881.63 and Dow ...

ResMed (RMD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Morgans analyst Iain Wilkie said 2024 was "pretty patchy" for the ASX healthcare sector, which underperformed broader markets ...

These 2 ASX shares are set to deliver a strong set of earnings in the next quarter according to experts. Let's dive in.

Let's see what steps you could take to build a winning portfolio. The post How I'd build a winning portfolio by investing in ...

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

The contact-free sleep monitoring systems market is projected to grow at an 8.1% CAGR, reaching $214.7 million by 2033 from ...

During five years of share price growth, ResMed achieved compound earnings per share (EPS) growth of 21% per year. This EPS growth is higher than the 8% average annual increase in the share price.

Nyxoah's disrupting Genio implant is likely to revolutionize Obstructive Sleep Apnea, and FDA's decision is expected in Q1 ...

The well-known name from a former "hot tech" era is attempting to bounce from the late October/early November new low.

With valuations stretched and geopolitical tensions high, the new year offers plenty of potholes for investors. So we asked ...

CorMedix is a member of the Medical sector. This group includes 1020 individual stocks and currently holds a Zacks Sector Rank of #2. The Zacks Sector Rank considers 16 different sector groups. The ...